The randomized DIALIZE-Outcomes trial evaluated sodium zirconium cyclosilicate in hemodialysis
Kidney International · 2025-10 · 108 (4) · 686-694
DOI: 10.1016/j.kint.2025.06.016 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Kidney International, 2025-10. Verfasst von Steven Fishbane und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York, USA. Electronic address: sfishbane@northwell.edu. Hauptthemen laut MEDLINE: Renal Dialysis, Silicates, Hyperkalemia, Arrhythmias, Cardiac. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AstraZeneca AG, AstraZeneca.
Abstract (Originalsprache)
INTRODUCTION: Patients receiving maintenance hemodialysis frequently experience predialysis hyperkalemia, with associated arrhythmias and cardiovascular events. The DIALIZE-Outcomes trial evaluated the effect of sodium zirconium cyclosilicate (SZC) on arrhythmia-related cardiovascular outcomes. METHODS: Adults receiving thrice-weekly hemodialysis with predialysis hyperkalemia (serum potassium was 5.5 mmol/l or more) were randomized 1:1 to SZC (5 g once daily on nondialysis days, then titrated weekly over 4 weeks between 0 and 15 grams to attain normokalemia [serum potassium 4.0-5.0 mmol/l]) or placebo. The primary outcome was a composite end point of sudden cardiac death, stroke, or arrhythmia-related hospitalization, intervention, or emergency department visit. Secondary end points included individual cardiovascular outcomes from the primary composite end point, and those reflecting serum potassium control. Safety was evaluated throughout. RESULTS: Overall, 2690 participants were randomized. The trial was terminated early due to low event rates (∼33% of planned) and high study medication discontinuation rates, limiting generalizability of the results. No treatment effect was observed on the primary composite end point (SZC, 8.8% [119 patients] vs. placebo, 8.9% [119 patients]; hazard ratio 0.98; 95% confidence interval 0.76-1.26) or individual cardiovascular outcomes. Maintenance of normokalemia at 12 months was significantly better with SZC than placebo (74.0% [495 patients] vs. 47.0% [293 patients]; odds ratio 3.36; 95% confidence interval 2.64-4.26). Serious adverse events occurred in 38.6% (SZC) and 37.6% (placebo) of participants; hypokalemia occurred in 3.0% (SZC) and 1.4% (placebo). CONCLUSIONS: SZC did not demonstrate a treatment effect on arrhythmia-related cardiovascular outcomes despite efficacy on serum potassium control. TRIAL REGISTRATION: Registered at ClinicalTrials.gov with study number NCT04847232.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Nephrology, Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York, USA. Electronic address: sfishbane@northwell.edu.
- Renal-Electrolyte and Hypertension Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Department of Nephrology, Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium.
- Division of Nephrology, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
- BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.
- BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Förderung
- AstraZeneca AG
- AstraZeneca
Zitieren
APA
Fishbane, S., Dember, L. M., Jadoul, M., Kovesdy, C. P., Guzman, N., Kordzakhia, G., Lisovskaja, V., Sekar, P., Wessman, P., Al-Shurbaji, A., & Herzog, C. A. (2025). The randomized DIALIZE-Outcomes trial evaluated sodium zirconium cyclosilicate in hemodialysis. Kidney International, 108(4), 686-694. https://doi.org/10.1016/j.kint.2025.06.016
Vancouver
Fishbane S, Dember LM, Jadoul M, Kovesdy CP, Guzman N, Kordzakhia G, et al. The randomized DIALIZE-Outcomes trial evaluated sodium zirconium cyclosilicate in hemodialysis. Kidney International. 2025;108(4):686-694. doi:10.1016/j.kint.2025.06.016
BibTeX
@article{Fishbane2025,
author = {Fishbane, Steven and Dember, Laura M and Jadoul, Michel and Kovesdy, Csaba P and Guzman, Nicolas and Kordzakhia, George and Lisovskaja, Vera and Sekar, Priya and Wessman, Peter and Al-Shurbaji, Ayman and Herzog, Charles A},
title = {The randomized DIALIZE-Outcomes trial evaluated sodium zirconium cyclosilicate in hemodialysis},
journal = {Kidney International},
year = {2025},
volume = {108},
number = {4},
pages = {686--694},
doi = {10.1016/j.kint.2025.06.016}
}
EUVIMED